# BOUNDLESS BIO, INC. (BOLD) · Edgar & Edgarette company card

> Figures from the company's own SEC filings.

SEC CIK 1782303 · fiscal year ended — · 0 audited years read · [page](https://www.pops4.com/boards/company/BOLD) · [JSON](https://www.pops4.com/boards/company/BOLD.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | — |
| Revenue growth, 1 year | — |
| Revenue growth per year | — |
| Operating margin | — |
| Net margin | — |
| Operating cash flow | — |
| Capital spending | — |
| Free cash flow | — |
| Cash | — |
| Long-term debt | — |
| Total assets | — |
| Total equity | — |
| Equity ÷ assets | — |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures


## Edgarette's reading

The filings carry no annual revenue line Edgarette can read (common for banks and insurers, which report income differently). Nothing weighed, nothing guessed.

## Health Watch, last 12 months

- Item 2.05 Restructuring or exit costs: 1, latest 2026-06-23 ([filing](https://www.sec.gov/Archives/edgar/data/1782303/000119312526278570/0001193125-26-278570-index.htm))
- Item 5.02 Director or officer change: 2, latest 2026-06-23 ([filing](https://www.sec.gov/Archives/edgar/data/1782303/000119312526278570/0001193125-26-278570-index.htm))

## Recent filings

- 8-K · filed 2026-08-28 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1782303/000119312526374787/0001193125-26-374787-index.htm)
- 10-Q · filed 2026-08-07 · [filing](https://www.sec.gov/Archives/edgar/data/1782303/000119312526339093/0001193125-26-339093-index.htm)
- 8-K · filed 2026-06-23 · 1.01 Entry into a Material Definitive Agreement; 2.05 Costs Associated with Exit or Disposal Activities; 3.02 Unregistered Sales of Equity Securities; 5.01 Changes in Control of Registrant; 5.02 Departure or Election of Directors; Appointment of Officers; 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1782303/000119312526278570/0001193125-26-278570-index.htm)
- 8-K · filed 2026-06-17 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1782303/000119312526273544/0001193125-26-273544-index.htm)
- 10-Q · filed 2026-05-08 · [filing](https://www.sec.gov/Archives/edgar/data/1782303/000119312526213321/0001193125-26-213321-index.htm)
- 8-K · filed 2026-05-08 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1782303/000119312526213269/0001193125-26-213269-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001782303.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1782303

## Cite

POPS4, Edgar & Edgarette: BOUNDLESS BIO, INC. (BOLD) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/BOLD. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.